Humanized complement 5A receptor 1 antibodies and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11912781-B2
Application number	US-202217575420-A
Country	US
Kind code	B2
Filing date	Jan 13, 2022
Priority date	Jan 13, 2021
Publication date	Feb 27, 2024
Grant date	Feb 27, 2024

Abstract

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

First claim

The invention claimed is:

1. A method of treating a C5a/C5aR1 mediated autoimmune disease, comprising administering an antibody or an antigen binding fragment thereof to a subject in need of the treatment, wherein the antibody or the antigen binding fragment thereof binds complement component 5a receptor 1 (C5aR1) and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises three heavy chain complementarity determining regions (HCDRs), wherein the HCDR1, HCDR2 and HCDR3 comprise SEQ ID NO: 6 (NYWMH), SEQ ID NO: 7 (YLNPSSGYTKYAQKFQG), and SEQ ID NO: 8 (SGGDNYGNPY YFDR), respectively, wherein the VL comprises three light chain complementary determining regions (LCDRs), wherein the LCDR1, LCDR2, and LCDR3 comprise SEQ ID NO: 9 (RASQSIVHSNGNTYLH), SEQ ID NO: 10 (KVSNRES), SEQ ID NO: 11 (AQYTLVPLT), respectively.

2. The method of claim 1 , wherein the VH comprises SEQ ID NO: 14, and the VL comprises SEQ ID NO: 25.

3. The method of claim 1 , wherein the disease is anti-neutrophilic cytoplasmic antibody vasculitis (ANCA vasculitis) or lupus.

4. The method of claim 1 , wherein the disease is stroke.

5. The method of claim 1 , wherein the antibody comprises an Fc domain selected from IgG1, IgG2, IgG2 and IgG4.

6. The method of claim 1 , wherein the antibody binds to C5aR1 and inhibits C5a mediated Gα signaling.

7. The method of claim 1 , wherein the antibody binds to C5aR1 and inhibits calcium signaling.

8. The method of claim 1 , wherein the antibody binds to C5aR1 and inhibits CD11b expression.

9. The method of claim 1 , wherein the antibody binds to C5aR1 and inhibits neutropenia.

10. The method of claim 1 , wherein the antibody binds to C5aR1 and inhibits β-arrestin signaling.

Assignees

• Visterra Inc

Inventors

• Viswanathan Karthik
• Booth Brian
• Ramakrishnan Boopathy
• Wollacott Andrew
• Babcock Gregory
• Shriver Zachary
• Olinski Lauren

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/77

  Internalization into the cell · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title